Veradermics MANE
NYSE MANE
$136.90 +9.79 (+7.70%)
As of: Oct 21, 2026 · 3:59 PM EDT

Veradermics (MANE) Capital Expenditures (2025 - 2026)

Updated

Veradermics' Capital Expenditures came in at $21,000 for Q2 2026.

Analysis

Veradermics (MANE) Capital Expenditures (2025 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Veradermics reported Capital Expenditures of $40,000; for FY2025, it was $24,000.

  • The Q2 2026 figure represents the lowest quarterly Capital Expenditures since Q1 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capex (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 2.93 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 1.32 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 322.00 Mn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 893.00 Mn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 321.00 Mn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 1.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 513.00 Mn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 140.00 Mn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 533.00 Mn
10 Veradermics 5.53 Bn 4.13 Bn - 21,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 21,000.00
Mar 31, 2025 19,000.00
API Access

Veradermics Capital Expenditures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=capital-expenditures&ticker=MANE&period=max&api_key=YOUR_API_KEY